TransEnterix (TRXC) is a US-based medical device company that focuses on digitizing the interfaces between the surgeon and the patient. The stock price increased ~5.6% and closed at $3.75 on June 1. The stock rose ~3.2% to $3.87 in the pre-market session on June 4.
The above chart shows analysts’ recommendations for TransEnterix in the past 12 months. On May 31, TransEnterix announced that Louisiana State University Health New Orleans School of Medicine purchased the Senhance Surgical System, which was developed by TransEnterix. TransEnterix’s stock price has increased ~623.8% in the past 12 months. So far, the stock has increased 94.3% in 2018.
Senhance Surgical System
The Senhance Surgical System was designed to assist surgeons in performing minimally invasive surgery. The system is installed at the University Medical Center in New Orleans. The surgeon controls small surgical instruments through multiple robotic arms. There’s a small scope that tracks the surgeon’s eye movement.
According to a press release, the Louisiana State University Health New Orleans School of Medicine plans to start a digital laparoscopy program using the Senhance Surgical System.
As of June 4, there are five analysts tracking TransEnterix stock. Two analysts recommended a “strong buy,” one analyst recommended a “buy,” and two analysts recommended a “hold.” None of the analysts recommended a “sell.” Analysts expect 5.9% growth in TransEnterix stock in the next 12 months with a target price of $4.13 per share—compared to the closing price of $3.75 per share on June 1.
The consensus rating for TransEnterix is 2.0, which represents a “buy” for momentum investors and long-term growth investors.
Notably, the SPDR Portfolio Small Cap ETF (SPSM) holds 0.01% of its total investments in TransEnterix, 0.02% in Utah Medical Products (UTMD), 0.02% in Fate Therapeutics (FATE), and 0.02% in Surgery Partners (SGRY).